Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H4FN3O2 |
Molecular Weight | 157.1028 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1c(F)nc(C(=O)N)c(n1)O
InChI
InChIKey=ZCGNOVWYSGBHAU-UHFFFAOYSA-N
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
Molecular Formula | C5H4FN3O2 |
Molecular Weight | 157.1028 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Favipiravir (originally known as T-705) is an orally administered novel anti-viral compound with a unique mechanism of action that is active against a wide range of RNA-based viruses in laboratory tests. Favipiravir has recently being approved in Japan under the brand name Avigan. Avigan is an experimental antiviral drug being developed by Toyama Chemical of Japan. It is a viral RNA polymerase inhibitor with a new mechanism of action, inhibiting viral gene replication within infected cells to prevent the propagation. Favipiravir is
phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5′- triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including
A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits
influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination
with oseltamivir, thereby expanding influenza treatment options. A Phase III clinical evaluation of
favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been
completed in the United States. In addition to its anti-influenza activity, favipiravir blocks the
replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde);
phleboviruses (Rift Valley fever, sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava,
and Prospect Hill); flaviviruses (yellow fever and West Nile); enteroviruses (polio- and
rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory
syncytial virus; and noroviruses.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428599 |
0.19 µM [EC50] | ||
Target ID: CHEMBL612765 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428599 |
0.083 µM [EC50] | ||
Target ID: CHEMBL2366902 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428599 |
0.5 µM [EC50] | ||
Target ID: CHEMBL613845 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19428599 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AVIGAN Approved UseTreatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which
other influenza antiviral drugs are ineffective or not sufficiently effective). Launch Date1.39561914E12 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. | 2003 Sep |
|
Antiviral strategies for pandemic and seasonal influenza. | 2010 Aug |
|
Combination chemotherapy for influenza. | 2010 Aug |
|
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. | 2010 Aug 26 |
|
Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. | 2010 Dec 21 |
|
A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes. | 2010 May |
|
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. | 2010 May |
|
Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. | 2010 Oct 7 |
|
[Present and future in development of new anti-influenza drugs]. | 2010 Sep |
|
Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. | 2010 Sep 16 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.pmda.go.jp/files/000210319.pdf
The usual adult dosage is 1600 mg of favipiravir administered orally twice daily on Day 1,
followed by 600 mg orally twice daily from Day 2 to Day 5. The total treatment duration should
be 5 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26752302
Favipiravir inhibited Ebola replication with EC50 36.8uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 23:00:03 UTC 2021
by
admin
on
Fri Jun 25 23:00:03 UTC 2021
|
Record UNII |
EW5GL2X7E0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
||
|
NCI_THESAURUS |
C25995
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
259793-96-9
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
C462182
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
Favipiravir
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
492405
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
DB12466
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
AVIGAN
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | APPROVED MARCH 2014 | ||
|
EW5GL2X7E0
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
8916
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
C81605
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
M11863
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
4887
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY | |||
|
CHEMBL221722
Created by
admin on Fri Jun 25 23:00:03 UTC 2021 , Edited by admin on Fri Jun 25 23:00:03 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
ANALOGUE->PARENT | |||
|
TARGET ORGANISM->INHIBITOR |
DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PRODRUG | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
IN HEALTHY JAPANESE VOLUNTEERS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||